Write to Karl Loren -- he will answer
Karl Loren: Below is yet another attack on intravenous chelation therapy, published by the nemesis of heath, the Journal of the American Medical Association. It is not always easy to research the truth about a report like this. I have the advantage of knowing that the final conclusion of this report is blatantly false. I do not have the advantage of seeing, immediately, where the fraud lies. But, since I know that there IS fraud, my research objective is to find the fraud. The JAMA people who obviously say that my research procedure is terribly flawed -- that any honest researcher would not start with that premise.
I suggest that the "scientific method," when reviewing an existing study, does start exactly and always with the premise that the "study" is flawed somewhere and they look for that flaw. Only in that way do we finally arrive at the truth. Some intravenous chelation doctors tried to refute the conclusions in the JAMA study, but, my observation, they did not succeed. Probably they didn't have access to the areas of the study where the flaw exists. I'm sure there is one.
You would think that the intravenous doctors would have the greatest interest is finding that flaw -- and that they would have the technical knowledge to do it. Sure enough, some of them wrote with their objections to JAMA, and, as JAMA would generally do (particularly when they see that the objection is weak), JAMA published those objections. (The second letter to the editor, objection, is here.) But, then the original authors of the attack on IV chelation had, of course, their chance to reply. They did. Their reply is HERE.
So, you say, how is Karl Loren to come up with a better objection than one of the Past Presidents of ACAM, American College for Advancement in Medicine, expert, surely? And other "experts?"
I'll tell you!
One of the most insidious ways anything can be destroyed is from within. If the IV doctors who objected to the JAMA article were, in fact, secretly trying to destroy the whole practice of intravenous chelation therapy, then you can guess that their study of the study, and their objections, would carefully NOT FIND the flaw. I include in that group of people who couldn't find the flaw some of their supporters whose "works" have been published supposedly to support the validity of IV chelation. One of them is the traitor, for sure, and probably more.
I believe that has happened. I will not publicly state who the traitor is, but I suggest that one of the people who couldn't find the real flaw has deliberately objected in a way that would look foolish. So, the truly valid therapy of intravenous chelation therapy is being destroyed from within the very group supposedly espousing it -- ACAM. I've written this before, and suggest you click here to review that article of mine. Also, click here about some valuable evidence of the validity of IV chelation, supposedly turned over to an ACAM member, but apparently never brought out in the open??
I even know WHY he is trying to destroy his own group -- and I believe that very few within that group recognizes what he is doing to them. So, I'll not reveal his name, but I leave you with that discovery of MINE -- the flaw of the JAMA study is yet to be found, but the bigger flaw is in the honesty and integrity of those who "tried" to refute it!
I received a private message from a well-meaning man who, himself, thought this study was doomed for failure and who thought I should do something about it! When there is a traitor in the midst of the IV doctors, they are in need of a far more omnipotent agent than I might be.
AFTER I had written all the above, I then found one HONEST IV doctor, Dr. Elmer Cranton, who has done a far more effective job of refuting the JAMA report below. It is fascinating! Dr. Cranton, undoubtedly, will not be willing to criticize the others who wrote into JAMA and got published -- among them are the ones who are secretly trying to kill intravenous chelation therapy. Dr. Cranton is not one of those. CLICK HERE for his refutation of the JAMA article below. The fact that I had come to the conclusion that the critics listed on this page included some dishonesty is now established by the article by Dr. Cranton. He is far more honest and more capable than these others!
The "study" below uses a term that needs explanation.
The first term needing definition is "ischemia."
The term is "exercise time to ischemia." Click here for one rather technical description. The simple definition is that exercise causes an increase of blood to flow to parts of the body. If you exercise and the blood flow does NOT increase, there must be some blockage. So, the doctors figure they know how much blood flow should increase from a set amount of exercise. If the blood flow does NOT increase to that amount, from that amount of exercise, in a particular amount of time, then the conclusion is that this person is at risk for a heart attack.
I will be writing more on this.
Karl Loren
Chelation Therapy for Ischemic Heart DiseaseA Randomized Controlled Trial
Chelation Therapy for Patients With Ischemic Heart Disease
Definition Of "Exercise Time To Ischemia"
Honest Refutation by Dr. Elmer Cranton -- Different Page
Vol.
287 No. 4,
January 23/30, 2002
Chelation Therapy for
Ischemic Heart Disease
A Randomized Controlled Trial
Merril L. Knudtson, MD; D. George
Wyse, MD, PhD; P. Diane Galbraith, BN; Rollin
Brant, PhD; Kathy Hildebrand, BN; Diana
Paterson, BScN; Deborah Richardson, RN;
Connie Burkart, BN; Ellen Burgess, MD; for
the Program to Assess Alternative Treatment
Strategies to Achieve Cardiac Health (PATCH)
Investigators
Context Chelation therapy using EDTA is an unproven but widely used alternative therapy for ischemic heart disease.
Objective To determine if current EDTA protocols have a favorable impact on exercise ischemia threshold and quality of life measures in patients with stable ischemic heart disease.
Design Double-blind, randomized, placebo-controlled trial conducted between January 1996 and January 2000.
Setting Participants were recruited from a cohort of cardiac catheterization patients and the practices of cardiologists in Calgary, Alberta.
Participants We screened 3140 patients, performed a qualifying treadmill test in 171, and enrolled 84. Entry criteria included age at least 21 years with coronary artery disease proven by angiography or a documented myocardial infarction and stable angina while receiving optimal medical therapy. The required treadmill test used a gradual ramping protocol and patients had to demonstrate at least 1-mm ST depression.
Interventions Patients were randomly assigned to receive infusion with either weight-adjusted (40 mg/kg) EDTA chelation therapy (n = 41) or placebo (n = 43) for 3 hours per treatment, twice weekly for 15 weeks and once per month for an additional 3 months. Patients in both groups took oral multivitamin therapy as well.
Main Outcome Measure Change from baseline to 27-week follow-up in time to ischemia (1-mm ST depression).
Results Thirty-nine patients in each group completed the 27-week protocol. One chelation patient had therapy discontinued for a transient rise in serum creatinine. The mean (SD) baseline exercise time to ischemia was 572 (172) and 589 (176) seconds in the placebo and chelation groups, respectively. The corresponding mean changes in time to ischemia at 27 weeks were 54 seconds (95% confidence interval [CI], 23-84 seconds; P<.001) and 63 seconds (95% CI, 29-95 seconds; P<.001), for a difference of 9 seconds (95% CI, -36 to 53 seconds; P = .69). Exercise capacity and quality of life scores improved by similar degrees in both groups.
Conclusion Based on exercise time to ischemia, exercise capacity, and quality of life measurements, there is no evidence to support a beneficial effect of chelation therapy in patients with ischemic heart disease, stable angina, and a positive treadmill test for ischemia.
JAMA. 2002;287:481-486
To the Editor:
Dr Knudtson and colleagues
1 reported that chelation therapy was ineffective in treating patients with ischemic heart disease. However, some of their findings suggest that chelation may do some good.First, there is some evidence that magnesium and ascorbic acid, which are common components of chelation therapy, may have beneficial effects.
2, 3 Patients in both the treatment and placebo groups received magnesium and ascorbic acid, and both groups improved.Second, Knudtson et al pointed out that there may be some delayed cardiac benefits from chelation due to EDTA. However, the authors failed to comment on the 9.4% angioplasty rate in the placebo group and the 0% rate in the treatment group at 1 year of follow-up.
I also question how well the authors followed the American College for Advancement in Medicine (ACAM) protocol.4 Randomization started in January 1996, with treadmill testing "at 15 and 27 weeks after randomization." It appears that study participants were receiving either chelation or placebo prior to the 1997 publication date of the ACAM protocol.
In addition, the study used lower doses of magnesium and ascorbic acid and EDTA adjustments for weight differed from those specified by the ACAM protocol. The authors similarly failed to adjust EDTA according to the creatinine clearance,1, 4 which may have led to the single complication of an elevated creatinine level in the treatment group.
Scott A. Bell, MD
AppleMed Preventive Medicine Clinic
Montgomery, Ala
1. Knudtson ML, Wyse DG, Galbraith
PD, et al. Chelation therapy for ischemic heart disease:
a randomized controlled trial. JAMA.
2002;287:481-486.
ABSTRACT | FULL
TEXT | PDF
| MEDLINE
2. Shechter M, Sharir M, Labrador
MJ, Forrester J, Silver B, Bairy Merz CN. Oral magnesium
therapy improves endothelial function in patients with
coronary artery disease. Circulation.
2000;102:2353-2358.
MEDLINE
3. Gokce N, Keaney JF Jr, Frei B,
et al. Long-term ascorbic acid administration reverses
endothelial vasomotor dysfunction in patients with
coronary artery disease. Circulation.
1999;99:3234-3240.
MEDLINE
4. Rozema TC. Protocols for
chelation therapy. J Adv Med. 1997;10:1-100.
To the Editor:
Dr Knudtson and colleagues
1 reported that chelation therapy with EDTA is no more effective than placebo in improving exercise time to ischemia, exercise capacity, and quality of life measurements in patients with ischemic heart disease.There are several problems with this study. First, the control group was not treated with a true placebo. Intravenous ascorbic acid (an antioxidant) and magnesium (an antihypertensive) may both have had beneficial effects. Second, the authors dismissed the statistically significant improvement from baseline in exercise time to ischemia in both groups as "consistent with a combination of placebo and training effects commonly seen in studies of angina patients." If it takes so little to achieve a statistically significant improvement perhaps this should not have been used as the primary end point of the study. Use of a different end point could have allowed the inclusion of more than 650 patients who either could not walk on a treadmill or did not meet the treadmill test requirements. A more meaningful end point would have been cardiac events (ie, death, myocardial infarction, angioplasty, or coronary artery bypass graft surgery).
After 1 year of follow-up the authors indicated 5 cardiac events in the control group but only 1 cardiac event in the chelation group. This may be due to increased plaque stability secondary to EDTA's inhibition of matrix metalloproteinase (MMP) activity. Although it has not been documented clinically, EDTA has been used in vitro to inhibit the activity of MMPs,2, 3 which are known to be metal dependent. The inhibition of MMP may be "particularly promising" in the prevention of the rupture of atherosclerotic plaques.4 Perhaps additional clinical studies using appropriate end points should be conducted before writing off EDTA chelation therapy as valueless.
In Reply:
Dr Bell and Dr Strassberg both conclude that adverse clinical events in our study were more frequent in the placebo group. In fact, 7 patients in the placebo group and 10 patients in the EDTA group had a major cardiac event (death, myocardial infarction, or need for revascularization or hospitalization for accelerating symptoms). A single item on the adverse event list, angioplasty, was performed in 4 patients in the placebo group but in none in the EDTA group, but this is not a statistically significant difference and it should not be cited as evidence that EDTA can be used to avoid cardiac procedures. Major adverse cardiac events were not end points in our study because it did not have sufficient statistical power to detect a difference in these low-frequency events.
We followed the 1989 ACAM protocol in effect at the time our study was initiated. We did not feel that the changes published in 1997 warranted changing our protocol in the middle of our study, a conclusion endorsed by the ACAM members of our steering committee who perform this procedure. The ascorbic acid dosage we used was greater than that recently shown to improve endothelial function.
By intent, the use of EDTA was the only difference between the 2 groups. Our study was not designed to evaluate the individual merits of magnesium, multivitamins, blood pressure and lipid monitoring, exercise, smoking cessation and dietary counseling, or any other educational and motivational aspects that are a part of the "chelation process." We acknowledged that one or more of these elements, or a training effect, may have been responsible for the observed modest general improvement in both groups. But it was clear that the use of EDTA had no significant independent impact on quality of life or treadmill test performance in patients with stable angina. We have made no broader indictment of the value of EDTA. Like many, we support the efforts to perform a larger trial with broader selection criteria and other clinical end points.
Merril L. Knudtson, MD
Division of Cardiology
University of Calgary
Calgary, Alberta
1. Kaufmann PA, Gnecchi-Ruscone T,
di Terlizzi M, Schafers KP, Luscher TF, Camici PG.
Coronary heart disease in smokers: vitamin C restores
coronary microcirculatory function. Circulation.
2000;102:1233-1238.
MEDLINE
[Karl
Note: "Perfusion" is defined as
volume
of blood supplying a unit mass (volume) of tissue per
unit time
ml of blood/min/100g(100ml) of tissue (source)
The Society of Vascular Surgery has been active for a number of years in standardizing the definitions of terms used in vascular care in an attempt to enable useful comparisons among studies as well as facilitate communication among physicians. Periodically it issues recommendations which are published The Journal of Vascular Surgery and represent the consensus opinion of the expert panel which sometimes includes Interventional Radiologists as in the most recent recommendations regarding the definitions of terms used in vascular access for hemodialysis and are available for review in the March 2002 issue of JVS. The definition of limb ischemia is both intuitive and in keeping with the sense in which physicians among all medical specialties have of the term.
Acute limb ischemia is any sudden decrease in limb perfusion causing a potential threat to extremity viability.
--JOURNAL OF VASCULAR SURGERY, Vol. 31, No. 1, Part 2, page S135
In their definition care is taken to distinguish limb-threatening ischemia from progressive claudication which can also suddenly worsen but does not have the serious consequences of sudden occlusion of a major arterial pathway. The complete text can be reviewed by clicking on the link above.
|
I promise to answer your message -- click here to send me a personal message
|
SUBSCRIBE: The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren. You can view more than 50 back issues of this publication by clicking here. The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter. It is automatically published on the Tuesday night just before the first Wednesday of every month. You can subscribe to this free monthly electronic letter by entering your eMail address and name below. You will then automatically receive a request for confirmation, sent to whatever address you have entered. If you do NOT receive this confirmation request, then you will not be subscribed. There may have been an error with your address and you should resubmit. The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription. When you receive this confirmation request you must reply to it, or your subscription will not become active. No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.
REMOVAL: You can remove yourself from the subscription list in several different ways. Click here to read about this entire newsletter system. Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list. If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed. Thus, no one else can unsubscribe you, from some other computer, without your knowledge. But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.
Personal Message: When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions. Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US. You can select particular information you would like to receive, along with the free cassette tape and catalog.
You can reach Vibrant Life in many ways, including by mail to Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504. Within the US and Canada, use the toll free number: (800) 523-4521, the local number: (818) 558-1799, the FAX: (818) 558-7299, eMail to kimberly@oralchelation.com or any one of the hundreds of message forms throughout the 50 web sites. Vibrant Life normally ships the same day we get an order. There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life. Check out our companion site, at: http://www.oralchelation.net where Karl's 2000 page book is published. Karl Loren is the author and webmaster for this BOOK, as well as for another web site about ORAL CHELATION. His personal philosophical articles are at PHILOSOPHY.
Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED. Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions: One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site. This permission does not extend to materials on this site which are copyrighted by others.
|
I promise to answer your message -- click here to send me a personal message
|
SUBSCRIBE: The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren. You can view more than 50 back issues of this publication by clicking here. The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter. It is automatically published on the Tuesday night just before the first Wednesday of every month. You can subscribe to this free monthly electronic letter by entering your eMail address and name below. You will then automatically receive a request for confirmation, sent to whatever address you have entered. If you do NOT receive this confirmation request, then you will not be subscribed. There may have been an error with your address and you should resubmit. The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription. When you receive this confirmation request you must reply to it, or your subscription will not become active. No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.
REMOVAL: You can remove yourself from the subscription list in several different ways. Click here to read about this entire newsletter system. Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list. If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed. Thus, no one else can unsubscribe you, from some other computer, without your knowledge. But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.
Personal Message: When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions. Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US. You can select particular information you would like to receive, along with the free cassette tape and catalog.
You can reach Vibrant Life in many ways, including by mail to Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504. Within the US and Canada, use the toll free number: (800) 523-4521, the local number: (818) 558-1799, the FAX: (818) 558-7299, eMail to kimberly@oralchelation.com or any one of the hundreds of message forms throughout the 50 web sites. Vibrant Life normally ships the same day we get an order. There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life. Check out our companion site, at: http://www.oralchelation.net where Karl's 2000 page book is published. Karl Loren is the author and webmaster for this BOOK, as well as for another web site about ORAL CHELATION. His personal philosophical articles are at PHILOSOPHY.
Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED. Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions: One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site. This permission does not extend to materials on this site which are copyrighted by others.
Causes
& symptoms